This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Many Nobel Laureates and many world renowned experts will participate at the conference.
The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include major research advances in biotechnology, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research.
The inaugural HISA Personalised Medicine conference is honoured to be co-chaired by Prof Richard Cotton and Prof Fernando Martin-Sanchez. The conference is part of the 21st Health Informatics Conference (HIC) 2013. The impressive line-up of national and international keynotes will address the role of informatics in delivering the future of personalised medicine.
Personalised medicine will have a significant impact on, and change the very nature of healthcare, the practice of medicine and how we live. The promise of personalised medicine has challenges and opportunities which health informatics must address as we continue to play a crucial role in this exciting space. The conference will cover the topics of data generation, integrating molecular and clinical data, analysing and visualising information and turning molecular information into medically actionable knowledge.
It is my pleasure to invite you to the second Up Close and Personalized, International Congress on Personalized Medicine, which will take place July 25-28, 2013 in Paris, France.
Personalized Medicine is revolutionizing the medical world. Understanding and integrating genetic and molecular information with traditional clinical knowledge is the hallmark of this transformation. At present much of the medical practice is based on standards of care derived from the epidemiologic studies of large cohorts that do not take into account the individual’s genetic, proteomic, and metabolic characteristics. Furthermore, in spite of efforts to develop data-driven, expert–based, clinical decision support systems, there are no clear and simple means to disseminate new findings into clinical practice.
The meeting will be focused on the need of acceleration of Pharmacogenomics and Theranostics clinical implementation based on the work of different groups of partners: clinicians, academics, pharmacologists, laboratory medicine specialists, pharmacists, industrial companies and patients. 5 scientific sessions are in the preparative phase and we have space for additional oral presentations reserved to the first arriving abstracts. Cellular models including Stem Cells are very useful and will complete the systems biology/systems medicine approach. A series of workshops are planified for showing the latest innovations on the tools necessary for the development of Pharmacogenomics.
Please send as soon as possible your abstract propositions. 12 of them will be selected for oral presentations and two awards will be attributed for the best poster presentation.
Chairman of the Congress